Your browser doesn't support javascript.
loading
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Pemmaraju, Naveen; Kantarjian, Hagop; Sweet, Kendra; Wang, Eunice; Senapati, Jayastu; Wilson, Nathaniel R; Konopleva, Marina; Frankel, Arthur E; Gupta, Vikas; Mesa, Ruben; Ulrickson, Matthew; Gorak, Edward; Bhatia, Sumeet; Budak-Alpdogan, Tulin; Mason, James; Garcia-Romero, Maria Teresa; Lopez-Santiago, Norma; Cesarman-Maus, Gabriela; Vachhani, Pankit; Lee, Sangmin; Bhatt, Vijaya Raj; Blum, William; Walter, Roland B; Bixby, Dale; Gojo, Ivana; Duvic, Madeleine; Rampal, Raajit K; de Lima, Marcos; Foran, James; Fathi, Amir T; Hall, Aric Cameron; Jacoby, Meagan A; Lancet, Jeffrey; Mannis, Gabriel; Stein, Anthony S; Mims, Alice; Rizzieri, David; Olin, Rebecca; Perl, Alexander; Schiller, Gary; Shami, Paul; Stone, Richard M; Strickland, Stephen; Wieduwilt, Matthew J; Daver, Naval; Ravandi, Farhad; Vasu, Sumithira; Guzman, Monica; Roboz, Gail J; Khoury, Joseph.
Afiliación
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sweet K; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Wang E; Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Wilson NR; Department of Internal Medicine, The University of Texas School of Health Sciences at Houston, Houston, TX.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Frankel AE; West Palm Beach VA Medical Center, West Palm Beach, FL.
  • Gupta V; MPN Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Mesa R; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX.
  • Ulrickson M; Banner MD Anderson Cancer Center, Gilbert, AZ.
  • Gorak E; Baptist MD Anderson Cancer Center, Jacksonville, FL.
  • Bhatia S; Community Health Network, Indianapolis, IN.
  • Budak-Alpdogan T; Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health University, Camden, NJ.
  • Mason J; Scripps MD Anderson Cancer Center, La Jolla, CA.
  • Garcia-Romero MT; Department of Dermatology, National Pediatrics Institute, Mexico City, Mexico.
  • Lopez-Santiago N; Division of Hematology/Oncology, Hematology Service, National Pediatrics Institute, Mexico City, Mexico.
  • Cesarman-Maus G; Department of Hematology, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Vachhani P; O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL.
  • Lee S; Division of Hematology and Oncology, Department of Medicine, Clinical and Translational Leukemia Program, Weill Cornell Medicine, New York, NY.
  • Bhatt VR; The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE.
  • Blum W; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA.
  • Walter RB; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Bixby D; Department of Hematology/Oncology, University of Michigan, Ann Arbor, MI.
  • Gojo I; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Duvic M; Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Rampal RK; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
  • de Lima M; Ohio State University, Columbus, OH.
  • Foran J; Department of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
  • Fathi AT; Harvard Medical School, Leukemia Program, Medicine, Massachusetts General Hospital, Boston, MA.
  • Hall AC; Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin School of Medicine and Public Health, Madison, WI.
  • Jacoby MA; Department of Medicine, Washington University Medical School, St. Louis, MO.
  • Lancet J; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Mannis G; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA.
  • Stein AS; Department of Hematology/Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA.
  • Mims A; Wexner Medical Center, James Cancer Hospital, The Ohio State University, Columbus, OH.
  • Rizzieri D; Novant Health Cancer Institute, Winston Salem, NC.
  • Olin R; Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA.
  • Perl A; Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Leukemia Program, Philadelphia, PA.
  • Schiller G; Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA.
  • Shami P; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • Stone RM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Strickland S; Vanderbilt-Ingram Cancer Center, Nashville, TN.
  • Wieduwilt MJ; Division of Bone Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Vasu S; Division of Hematology, Bone Marrow Transplantation and Cellular Therapies Program, The Ohio State University James Cancer Hospital, Columbus, OH.
  • Guzman M; Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY.
  • Roboz GJ; Division of Hematology and Medical Oncology, Leukemia Program, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY.
  • Khoury J; Division of Pathology/Lab Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood ; 141(6): 567-578, 2023 02 09.
Article en En | MEDLINE | ID: mdl-36399715
ABSTRACT
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC's inaugural meetings are presented herein.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Neoplasias Hematológicas / Trastornos Mieloproliferativos Tipo de estudio: Prognostic_studies Límite: Aged / Child / Humans País/Región como asunto: America do norte Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Neoplasias Hematológicas / Trastornos Mieloproliferativos Tipo de estudio: Prognostic_studies Límite: Aged / Child / Humans País/Región como asunto: America do norte Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article